Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus-Reference-Cited by-同舟云学术

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

Published:2021-05-26 Issue:595 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Karnell Jodi L.¹^ORCID,Wu Yanping¹,Mittereder Nanette¹^ORCID,Smith Michael A.¹,Gunsior Michele¹^ORCID,Yan Li¹,Casey Kerry A.²^ORCID,Henault Jill²,Riggs Jeffrey M.²,Nicholson Simone M.²^ORCID,Sanjuan Miguel A.²,Vousden Katherine A.³^ORCID,Werth Victoria P.⁴^ORCID,Drappa Jörn¹^ORCID,Illei Gabor G.¹^ORCID,Rees William A.¹,Ratchford John N.¹^ORCID,Chatham W. Winn,Chindalore Vishala,Gupta Ramesh,Jeka Slawomir,Kivitz Alan,Ford Theresa Lawrence,Marano Anne,de la Fuente Jose Luis Marenco,Mathews Steven,Reich Adam,Rudinskaya Alla,Rudnicka Lidia,Terrelonge Antonio,

Affiliation:

1. Viela Bio, Gaithersburg, MD 20878, USA.

2. AstraZeneca, Gaithersburg, MD 20878, USA.

3. AstraZeneca, Cambridge CB21 6GH, UK.

4. Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

VIB7734 depletes plasmacytoid dendritic cells and demonstrates clinical benefit in patients with cutaneous lupus.

Funder

Viela Bio

Publisher

American Association for the Advancement of Science (AAAS)

Subject